Home » Stocks » Cellectis

Cellectis S.A. (CLLS)

Stock Price: $16.91 USD -0.87 (-4.89%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed
Pre-market: $16.95 +0.04 (0.24%) Aug 7, 6:50 AM

Stock Price Chart

Key Info

Market Cap 718.09M
Revenue (ttm) 82.19M
Net Income (ttm) -73.58M
Shares Out 42.47M
EPS (ttm) -1.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 6, 2020
Last Price $16.91
Previous Close $17.78
Change ($) -0.87
Change (%) -4.89%
Day's Open 17.80
Day's Range 16.84 - 17.95
Day's Volume 110,787
52-Week Range 7.32 - 21.97

More Stats

Market Cap 718.09M
Enterprise Value 453.14M
Earnings Date (est) Nov 24, 2020
Ex-Dividend Date n/a
Shares Outstanding 42.47M
Float 27.36M
EPS (basic) n/a
EPS (diluted) -1.58
FCF / Share -2.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 359,280
Short Ratio 1.67
Short % of Float n/a
Beta 1.85
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.74
PB Ratio 2.01
Revenue 82.19M
Operating Income -94.23M
Net Income -73.58M
Free Cash Flow -85.25M
Net Cash 264.95M
Net Cash / Share 6.24
Gross Margin 72.09%
Operating Margin -114.64%
Profit Margin -89.50%
FCF Margin -103.72%
ROA -10.94%
ROE -20.15%
ROIC -37.40%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (13)

Buy 10
Overweight 1
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

(87.23% upside)
Current: $16.91
Target: 31.66
*Average 12-month USD price target from 12 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Revenue Growth7.27%-36.43%-40.27%-9.78%136.51%107.9%-
Gross Profit11.6018.6931.1056.4462.5726.4512.72
Operating Income-124-105-92.65-67.30-30.98-5.25-26.53
Net Income-102-78.69-99.37-67.26-22.800.02-55.40
Shares Outstanding42.4342.4135.3435.1834.1526.07-
Earnings Per Share-2.41-1.93-2.78-1.91-0.67--2.68
Operating Cash Flow-69.14-68.14-52.33-32.713.5941.73-18.85
Capital Expenditures-12.50-3.454.78-13.67-4.21-0.31-0.57
Free Cash Flow-81.64-71.59-47.55-46.38-0.6141.42-19.42
Cash & Equivalents3614522972913141127.56
Total Debt47.611.350.031.761.993.694.07
Net Cash / Debt3134512972893121093.49
Book Value31540926527326360.792.74
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name Cellectis S.A.
Country France
Employees 253
CEO André Choulika

Stock Information

Ticker Symbol CLLS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CLLS
IPO Date February 7, 2007


Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.